Skip to main content
Amgen10-Q: Regulatory investigation

FDA Proposes to Withdraw Approval of TAVNEOS and Alerts on Liver Injury Cases

Source: Autobound Signal API · 83 signals tracked for Amgen · updated

Get Amgen's live signals in Claude or ChatGPT, or by API

AskWhat changed at Amgen this week? Use Autobound signals for amgen.com.

What happened

On April 27, 2026, CDER issued a proposal to withdraw approval of TAVNEOS alleging lack of substantial evidence of effectiveness and untrue statements of material facts, following a March 31, 2026 DSC on serious liver injury cases. This regulatory scrutiny may drive immediate demand for regulatory compliance, legal consulting, and pharmacovigilance safety solutions.

Source

SEC EDGARApr 30, 2026

Quarterly report (Form 10-Q)

Amgen 10-Q for Quarter ended Mar 31, 2026

Filing excerpt

On April 27, 2026, CDER issued a proposal to withdraw approval of TAVNEOS, alleging that there is new information indicating lack of substantial evidence of effectiveness for the drug and that ChemoCentryx’s application that resulted in FDA approval contained untrue statements of material facts.

sec.gov/Archives/edgar/data/318154/000031815426000057/amgn-20260331.htmRead the full source

Other signals in this filing (4)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Regulatory investigation

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Mar 31, 2026
Fiscal year end
03/31
Filed
Apr 30, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Details

CIK
318154
Accession number
0000318154-26-000057
Timeframe
Current quarter
Quarter
Q1
Filing year
2026
Period end date
Mar 31, 2026
Why it matters
Compliance tools urgently needed
Signal category
Risk

Topics and mentions

Regions named

  • United States
  • Japan

Extraction

Confidence
High
Relevance
85%
Sentiment
Negative
Detected
Nov 9, 2026
signal_type
sec-10q
signal_subtype
regulatoryInvestigation

Use this data

Get every 10-Q signal for Amgen and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Amgen this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/491f3dd2-c374-4f21-abb9-f10b2f225e1e returns this record as JSON. POST /v1/companies/enrich returns every signal for amgen.com.

{
  "signal_id": "491f3dd2-c374-4f21-abb9-f10b2f225e1e",
  "signal_type": "sec-10q",
  "signal_subtype": "regulatoryInvestigation",
  "detected_at": "2026-11-09T06:24:49.379+00:00",
  "company": {
    "name": "Amgen",
    "domain": "amgen.com"
  },
  "data": {
    "detail": "On April 27, 2026, CDER issued a proposal to withdraw approval of TAVNEOS alleging lack of substantial evidence of effectiveness and untrue statements of material facts, following a March 31, 2026 DSC on serious liver injury cases. This regulatory scrutiny may drive immediate demand for regulatory compliance, legal consulting, and pharmacovigilance safety solutions.",
    "metrics": {
      "timeframe": "current_quarter"
    },
    "quarter": "Q1",
    "summary": "FDA Proposes to Withdraw Approval of TAVNEOS and Alerts on Liver Injury Cases",
    "excerpts": "On April 27, 2026, CDER issued a proposal to withdraw approval of TAVNEOS, alleging that there is new information indicating lack of substantial evidence of effectiveness for the drug and that ChemoCentryx’s application that resulted in FDA approval contained untrue statements of material facts.",
    "relevance": 0.85,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/318154/000031815426000057/amgn-20260331.htm",
    "filing_date": "2026-04-30",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "03/31",
    "period_end_date": "2026-03-31",
    "sales_relevance": "Compliance tools urgently needed",
    "signal_category": "risk",
    "regions_mentioned": [
      "United States",
      "Japan"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.